Cardiff Oncology Files 8-K for Bylaws and Financials
Ticker: CRDF · Form: 8-K · Filed: Jan 6, 2025 · CIK: 1213037
| Field | Detail |
|---|---|
| Company | Cardiff Oncology, Inc. (CRDF) |
| Form Type | 8-K |
| Filed Date | Jan 6, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, financial-reporting, bylaws
Related Tickers: CRDF
TL;DR
CRDF filed an 8-K for bylaw changes and financials as of Jan 3, 2025.
AI Summary
Cardiff Oncology, Inc. filed an 8-K on January 6, 2025, reporting amendments to its articles of incorporation or bylaws and financial statements as of January 3, 2025. The company, formerly known as Trovagene, Inc., is incorporated in Delaware and operates in the biological products sector.
Why It Matters
This filing indicates routine corporate updates and financial reporting, providing transparency to investors about the company's governance and financial status.
Risk Assessment
Risk Level: low — The filing pertains to standard corporate actions and financial reporting, not indicating any immediate operational or financial distress.
Key Numbers
- 001-35558 — SEC File Number (Identifies the company's filing history with the SEC.)
- 27-2004382 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Cardiff Oncology, Inc. (company) — Registrant
- Trovagene, Inc. (company) — Former company name
- January 03, 2025 (date) — Date of earliest event reported
- January 6, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
FAQ
What specific amendments were made to Cardiff Oncology's articles of incorporation or bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the summary text of the 8-K.
What is the significance of the 'Financial Statements and Exhibits' item in this 8-K filing?
This item signifies that Cardiff Oncology is providing updated financial information and related documents as of January 3, 2025, which is crucial for investors to assess the company's financial health.
When was Cardiff Oncology, Inc. previously known as?
Cardiff Oncology, Inc. was formerly known as Trovagene, Inc., and prior to that, TrovaGene Inc. and XENOMICS INC.
What is Cardiff Oncology's primary business sector?
Cardiff Oncology, Inc. operates in the BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) sector, with the SIC code 2836.
Where is Cardiff Oncology, Inc. headquartered?
Cardiff Oncology, Inc. is headquartered at 11055 Flintkote Avenue, San Diego, California, 92121.
Filing Stats: 414 words · 2 min read · ~1 pages · Grade level 11 · Accepted 2025-01-06 16:10:07
Filing Documents
- crdf-20250103.htm (8-K) — 39KB
- crdf-ex3_1.htm (EX-3.1) — 163KB
- 0000950170-25-002076.txt ( ) — 338KB
- crdf-20250103.xsd (EX-101.SCH) — 24KB
- crdf-20250103_htm.xml (XML) — 5KB
03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On January 3, 2025, the Board of Directors of Cardiff Oncology, Inc. (the "Company") approved the Amended and Restated By-laws of the Company. A copy of the Amended and Restated By-laws of the Company is filed as Exhibit 3.1 to this Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. 3.1 Amended and Restated By-laws of Cardiff Oncology, Inc. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CARDIFF ONCOLOGY, INC. Date: January 6, 2025 By: /s/ Mark Erlander Mark Erlander Chief Executive Officer 3